跳至主要内容
临床试验/NCT02616757
NCT02616757撤回不适用

Quantitative Ultrasound for the Evaluation of Simple Bone Cyst Healing

The Hospital for Sick Children1 个研究点 分布在 1 个国家开始时间: 2016年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
Z-scores obtained using quantitative ultrasound

研究概览

简要总结

Simple bone cysts (SBCs), also known as unicameral bone cysts (UBCs), are benign bone lesions. Literature to date describes little agreement between clinicians on specific prognostic criteria for the prediction of cyst healing, recurrence or fracture. Evidence has shown that bone mineral density (BMD) is a reliable indicator of risk to SBC patients given its association with the mechanical properties of bone. There has been further exploration into the use of quantitative ultrasound to assess bone density by measuring the velocity of the ultrasound transmission over the bone. To determine whether the QUS can provide prognostic information with respect to cyst healing, recurrence or fracture with a SBC, further study is needed.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
2 Years 至 21 Years(Child, Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Arm 1 - Simple Bone Cyst Patients
  • •Inclusion Criteria
  • •Patients ≥ 2 and ≤ 21 years
  • •Patients with a diagnosis of simple bone cyst located in a long bone confirmed by imaging within 3 months prior to registration
  • •All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.

排除标准

  • •Patients with implants to stabilize the bone where the cyst is located.
  • •Patients with bone disease (i.e. osteogenesis imperfecta, cancer, osteoporosis, Paget's disease)
  • •Patients who are pregnant or breastfeeding
  • •Patients with a simple bone cyst crossing the growth plate
  • •Arm 2 - Healthy Controls
  • •Inclusion Criteria
  • •Patients ≥ 2 and ≤ 21 years
  • •All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
  • •Exclusion Criteria
  • •Patients with bone disease (i.e. osteogenesis imperfecta, cancer, osteoporosis, Paget's disease)
  • •Patients receiving any bone-modifying agents (i.e. steroids, bisphosphanates, etc.)
  • •Patients who are pregnant or breastfeeding
  • •Arm 3 - Fracture patients
  • •Inclusion Criteria
  • •Patients ≥ 2 and ≤ 21 years
  • •Patients who have undergone any type of casting or surgical treatment for their fracture
  • •All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
  • •Exclusion Criteria
  • •Patients with bone disease (i.e. osteogenesis imperfecta, cancer, osteoporosis, Paget's disease)
  • •Patients receiving any bone-modifying agents (i.e. steroids, bisphosphanates, etc.)
  • •Patients who are pregnant or breastfeeding

研究组 & 干预措施

Simple Bone Cyst Patients

Active Comparator

Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline and once annually for 2 years.

There will also be optional blood samples taken o measure bone alkaline phosphatase.

干预措施: Sunlight Omnisense Quantitative Ultrasound (Device)

Fracture patients

Active Comparator

Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at future follow-up visits as clinically indicated or at a one year follow-up visit.

There will also be optional blood samples taken to measure bone alkaline phosphatase.

干预措施: Sunlight Omnisense Quantitative Ultrasound (Device)

Health volunteers

Placebo Comparator

Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at a one year follow-up visit.

There will also be optional blood samples taken to measure bone alkaline phosphatase.

干预措施: Sunlight Omnisense Quantitative Ultrasound (Device)

结局指标

主要结局

Z-scores obtained using quantitative ultrasound

时间窗: 2 years

次要结局

  • Bone specific alkaline phosphatase(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

James Wright

Orthopaedic Surgeon

The Hospital for Sick Children

研究点 (1)

Loading locations...

相似试验